How effective is nivolumab in treating gastric cancer?

The effect of Nivolumab (Nivolumab) in the treatment of gastric cancer is constantly being studied and verified. Gastric cancer is a common malignant tumor and difficult to treat. However, nivolumab, as an immune checkpoint inhibitor, brings new treatment hope to gastric cancer patients.

Clinical trial data show that nivolumab has achieved certain efficacy in the treatment of gastric cancer. A key clinical trial is the ATTRACTION-2 study, which investigated nivolumab in the treatment of advanced gastric or esophagogastric cancer. The results of the study showed that compared with conventional chemotherapy, the overall survival of patients in the nivolumab treatment group was significantly longer, and the progression-free survival was also significantly improved. Especially in patients with positive expression of PD-L1, the therapeutic effect of nivolumab is more significant.

In addition, the application of nivolumab in the treatment of gastric cancer continues to expand. Some early trials and clinical studies suggest that nivolumab may have a role in second-line treatment of gastric cancer, especially in patients with metastatic gastric cancer after failure of chemotherapy, where nivolumab may become an effective treatment option.

However, it is worth noting that the efficacy of nivolumab in the treatment of gastric cancer requires further research and verification. In actual clinical applications, factors such as patient differences, tumor characteristics, and treatment options will affect the treatment effect. Therefore, patients need to select individualized treatment plans under the guidance of doctors when receiving treatment, and pay close attention to the treatment effects and occurrence of adverse reactions, so as to adjust treatment strategies in a timely manner and maximize treatment effects and survival rates.